Q702 for blood cancers and histiocytic disorders
Part of Blood & lymphatic, Cancer, Heart & circulation, Immune system & allergy, Lungs & breathing, Skin clinical trials.
This study tests an experimental pill called Q702 for people with certain blood cancers and related disorders (like histiocytoses, myelofibrosis, and lymphomas) that have not responded to standard treatments. It aims to see if Q702 is safe and effective.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 years or older.
- You must have one of several specified blood cancers or histiocytic disorders (such as Erdheim-Chester disease, myelofibrosis, or lymphoma) and have tried at least 2 prior treatments that didn't work or aren't suitable.
- You need to be able to swallow pills and be willing to provide extra blood, bone marrow, and tissue samples for research.
- Your blood counts, kidney and liver function must be within certain limits, and you cannot have serious heart problems or other active cancers.
- You must agree to use effective contraception if you are of childbearing potential, and not be pregnant or nursing.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new medicine (Q901) that targets a specific cell-control pathway to treat advanced cancers that have stopped responding to standard care. It’s mainly for people with certain solid tumor cancers, aiming to see whether the drug can shrink tumors or control disease.
This trial tests an experimental drug called QN-302 in people with advanced solid tumors that have grown despite standard treatments or for which no standard therapy exists. The goal is to see if it is safe and how the body processes it.
This trial tests a new drug called QLS2309 for people with certain blood cancers that have come back or not responded to other treatments. The drug targets a protein called CD70 on the cancer cells, and this study aims to find the safest dose.
This Phase 2 study tests a treatment aimed at specific FGFR (a cancer-growth signal) changes found in your tumor. It may help people whose cancer has spread, cannot be removed, or has stopped responding to standard treatment.
This trial tests an experimental oral capsule called TQB3019 for people with advanced blood cancers that have come back or not improved with other treatments. The goal is to see if the drug is safe and to find the right dose.
This trial tests a combination of two new treatments (QLP2117 and QL2107) for people with advanced solid tumors that have not responded to standard therapy. The goal is to see if the combination can shrink tumors or slow cancer growth.
Hear when a new Hematopoietic and Lymphatic System Neoplasm trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.